Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01412060 · ClinicalTrials.gov registry record · Phase 3
A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia
A Phase 3 study of Schizophrenia, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 765
- Enrollment target
- 20
- Study locations
NCT01412060 is a Phase 3 study of Schizophrenia that has completed, run by Forest Laboratories. The registered enrollment target is 765 participants, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (253% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT01412060, a Phase 3 study of Schizophrenia, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 765 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the efficacy and safety of cariprazine relative to placebo in the prevention of relapse of symptoms in participants with schizophrenia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cariprazine
Study Locations (20)
California
- Forest Investigative Site 018 - Cerritos
- Forest Investigative Site 007 - Costa Mesa
- Forest Investigative Site 026 - Culver City
- Forest Investigative Site 008 - Long Beach
- Forest Investigative Site 002 - Oceanside
- Forest Investigative Site 019 - Orange
- Forest Investigative Site 001 - Paramount
- Forest Investigative Site 020 - San Diego
Maryland
- Forest Investigative Site 023 - Baltimore
- Forest Investigative Site 010 - Rockville
Missouri
- Forest Investigative Site 006 - Creve Coeur
- Forest Investigative Site 014 - St Louis
Arkansas
- Forest Investigative Site 011 - Little Rock
District of Columbia
- Forest Investigative Site 005 - Washington D.C.
Florida
- Forest Investigative Site 024 - Leesburg
Georgia
- Forest Investigative Site 017 - Atlanta
Illinois
- Forest Investigative Site 021 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 765 participants |
| Start Date | 2011-09-27 |
| Est. Completion | 2014-09-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01412060
The ClinicalTrials.gov registry entry for NCT01412060 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 765 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (253% higher). The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01412060 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Maryland, Missouri.
Frequently Asked Questions
What is clinical trial NCT01412060 about?
NCT01412060 is a clinical study titled "A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia". The objective of this study is to evaluate the efficacy and safety of cariprazine relative to placebo in the prevention of relapse of symptoms in participants with schizophrenia.
What is the current status of trial NCT01412060?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 765 participants. The study started on 2011-09-27. Estimated completion is 2014-09-03.
What conditions does trial NCT01412060 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT01412060?
The interventions under investigation include: Placebo (DRUG), Cariprazine (DRUG).
Who is sponsoring clinical trial NCT01412060?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01412060 being conducted?
This trial has 20 study locations across Arkansas, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.